AR062165A1 - Extracto de eucalipto, su procedimiento de preparacion y sus utilizaciones terapeuticas - Google Patents

Extracto de eucalipto, su procedimiento de preparacion y sus utilizaciones terapeuticas

Info

Publication number
AR062165A1
AR062165A1 ARP070103382A ARP070103382A AR062165A1 AR 062165 A1 AR062165 A1 AR 062165A1 AR P070103382 A ARP070103382 A AR P070103382A AR P070103382 A ARP070103382 A AR P070103382A AR 062165 A1 AR062165 A1 AR 062165A1
Authority
AR
Argentina
Prior art keywords
isobutyl
group
extract
preparation procedure
forms
Prior art date
Application number
ARP070103382A
Other languages
English (en)
Inventor
Christel Fiorini-Puybaret
Bernard Fabre
Cecile Chauvin
Philippe Joulla
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AR062165A1 publication Critical patent/AR062165A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)

Abstract

Utilizacion de un extracto deeucalipto para la preparacion de un medicamento destinado al tratamiento y/o a la prevencion de las afecciones o patologías que se derivan de un trastorno en la reabsorcion de neurotransmisores. La presente invencion se refiereigualmente a un nuevo extracto de eucalipto enriquecido caracterizado porque contiene al menos un compuesto de la formula (1) o una cualquiera de sus formas diastereoisoméricas: en la que R1 forma con el átomo de carbono al que está unido un grupo C=CH2, un grupo de formulas (2) y R2 representa un grupo isobutilo, alfa-isobutilo o beta-isobutilo; así como a su procedimiento de preparacion. Reivindicacion 4: Utilizacion segun la reivindicacion 3, caracterizada porque el compuesto de la formula (1) es el macrocarpal A (5-((1R)-1-((11S,7R)-7-hidroxi-3,3,7,11-tetrametiltriciclo(6.3.0.0(2,4))undec-11-il)-3-metilbutil)-2,4,6-trihidroxibenceno-1,3-dicarbaldehído) en el que R1 forma con el átomo de carbono al que está unido el grupo (3) y R2 representa un beta-isobutilo; y porque su fraccion másica en el extracto de eucalipto es superior o igual a 0,1% y estrictamente inferior a 3%.
ARP070103382A 2006-08-01 2007-08-01 Extracto de eucalipto, su procedimiento de preparacion y sus utilizaciones terapeuticas AR062165A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0607201A FR2904557B1 (fr) 2006-08-01 2006-08-01 Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques

Publications (1)

Publication Number Publication Date
AR062165A1 true AR062165A1 (es) 2008-10-22

Family

ID=37708427

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103382A AR062165A1 (es) 2006-08-01 2007-08-01 Extracto de eucalipto, su procedimiento de preparacion y sus utilizaciones terapeuticas

Country Status (20)

Country Link
US (1) US20090324754A1 (es)
EP (1) EP2049133A2 (es)
JP (1) JP2010500974A (es)
KR (1) KR20090034401A (es)
CN (1) CN101511378A (es)
AR (1) AR062165A1 (es)
AU (1) AU2007283529A1 (es)
BR (1) BRPI0714863A2 (es)
CA (1) CA2659162A1 (es)
FR (1) FR2904557B1 (es)
IL (1) IL196788A0 (es)
MA (1) MA30592B1 (es)
MX (1) MX2009000673A (es)
NO (1) NO20090951L (es)
NZ (1) NZ574429A (es)
RU (1) RU2445112C2 (es)
TN (1) TN2009000018A1 (es)
TW (1) TW200820961A (es)
UA (1) UA99598C2 (es)
WO (1) WO2008017752A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926547B1 (fr) * 2008-01-18 2010-04-23 Pf Medicament 5-°1-(decahydro-7-hydroxy-1,1,3a,7-tetramethyl-1h- cyclopropa°a!naphtalen-4-yl)-3-methylbutyl!-2,4,6-trihydroxy -1,3-benzenedicarboxaldehyde en tant que medicaments.
JP5602346B2 (ja) 2008-06-17 2014-10-08 株式会社ロッテ ユーカリ抽出物の調製方法
GB2465228A (en) * 2008-11-15 2010-05-19 Athena Health Patents Inc Analogues of phloroglucinols from eucalyptus plant varieties and related compounds and their use in treating neurodegenerative disorders
CN102085169B (zh) * 2011-01-30 2012-08-29 广州中涵生物科技有限公司 一种使黑头溶解同步收细毛孔的制剂
PT106278B (pt) * 2012-04-26 2018-01-03 Raiz Inst De Investigação Da Floresta E Papel Método para a obtenção de um extrato rico em ácidos triterpénicos a partir da casca de eucalipto
KR102115037B1 (ko) * 2013-12-04 2020-05-25 코웨이 주식회사 상고머리 야테 추출물을 유효성분으로 함유하는 피부 미백용 화장료 조성물
US20160317596A1 (en) * 2013-12-18 2016-11-03 Thylabisco Ab Use of Thylakoids to Reduce the Urge for Palatable Food
US10143706B2 (en) 2016-06-29 2018-12-04 Cannscience Innovations, Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
CN109172554A (zh) * 2018-09-06 2019-01-11 淮安安莱生物科技有限公司 大果桉醛c在制备治疗人肝癌的药物方面的应用
KR102212193B1 (ko) 2019-07-15 2021-02-03 박경호 인동등 및 유칼립투스 추출물을 유효성분으로 포함하는 인지기능장애 예방 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329297A1 (fr) * 1975-10-29 1977-05-27 Rougier Yves Inhalateur buccal
JP3365782B2 (ja) * 1990-11-22 2003-01-14 株式会社ロッテ 新規マクロカルパール類及びその製造法
DE4447336C2 (de) * 1994-12-31 1996-12-19 Goebel Hartmut J Dr Med Habil Verwendung eines Gemisches aus Cineol und Menthol
JPH08198765A (ja) * 1995-01-31 1996-08-06 Hayami Kinugawa 鎮痛用医薬組成物
JPH11137232A (ja) * 1997-08-02 1999-05-25 Ever Bright Ind Corp ハーブ製品
JP4809980B2 (ja) * 2000-01-18 2011-11-09 長岡香料株式会社 抗動脈硬化症剤
US20010036488A1 (en) * 2000-01-18 2001-11-01 Syuichi Hayashi Anti-obestic composition
CA2470603A1 (en) * 2001-12-19 2003-07-03 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
JP4979181B2 (ja) * 2003-01-31 2012-07-18 株式会社ヤクルト本社 グリケーション阻害剤及びその利用
JP2005272431A (ja) * 2004-03-24 2005-10-06 Yukio Kitagawa アロマセラピー品

Also Published As

Publication number Publication date
RU2445112C2 (ru) 2012-03-20
BRPI0714863A2 (pt) 2013-05-21
FR2904557A1 (fr) 2008-02-08
US20090324754A1 (en) 2009-12-31
RU2009107166A (ru) 2010-09-10
NZ574429A (en) 2012-01-12
WO2008017752A3 (fr) 2008-04-10
KR20090034401A (ko) 2009-04-07
FR2904557B1 (fr) 2010-04-30
UA99598C2 (ru) 2012-09-10
EP2049133A2 (fr) 2009-04-22
NO20090951L (no) 2009-04-24
TN2009000018A1 (fr) 2010-08-19
WO2008017752A2 (fr) 2008-02-14
TW200820961A (en) 2008-05-16
CN101511378A (zh) 2009-08-19
MA30592B1 (fr) 2009-07-01
AU2007283529A1 (en) 2008-02-14
JP2010500974A (ja) 2010-01-14
IL196788A0 (en) 2009-11-18
CA2659162A1 (fr) 2008-02-14
MX2009000673A (es) 2009-02-04

Similar Documents

Publication Publication Date Title
AR062165A1 (es) Extracto de eucalipto, su procedimiento de preparacion y sus utilizaciones terapeuticas
EA201070988A1 (ru) Противовирусные терапевтические средства
UY28473A1 (es) Nuevos compuestos
EA201491335A1 (ru) Бигуанидные композиции и способы лечения метаболических расстройств
EA201370208A1 (ru) Формы рифаксимина и их применение
UY29079A1 (es) Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
CO6270312A2 (es) Moduladores de gpr40 bifenilo-sustituidos
DOP2010000165A (es) 4-(4-ciano-2-tioaril) dihidropirimidinonas y su uso como inhibidores de la elastasa neutrofila humana
UY30812A1 (es) Sulfonatos { 2-amino-4-[r-fenil]-1-metil-5-oxo-4,5-dihidro-1 h-imidazol-4-il}fenil sustituidos, composiciones conteniéndolos y aplicaciones
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
UY31065A1 (es) Heterociclos ciclicos
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
CO6220948A2 (es) Derivados de ciclohexano espirociclico
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
EA200900065A1 (ru) Ингибиторы глицинового переносчика-1
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
PA8793101A1 (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal